The Latest Breaking News from EVLO

Evelo Biosciences: Q1 Earnings Insights

  Evelo Biosciences (NASDAQ:EVLO) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 12, 2022

Read Why Did Evelo Discontinue EDP1867 Atopic Dermatitis Program

Evelo Biosciences Inc (NASDAQ:EVLO) will put the EDP1867 program on hold after completing a Phase 1 clinical trial in atopic dermatitis. Data from the Phase 1b clinical trial of EDP1867 (n=52, with 40 participants who had at least one dose of EDP1867) showed it was safe and well-tolerated in both healthy volunteers and…

Benzinga · Apr 14, 2022

Evelo Biosciences Shares Gain After Positive Data On Faster Release EDP1815 Capsule, Q4 Earnings

In the Q4 earnings release, Evelo Biosciences Inc (NASDAQ:EVLO) shared results from an ongoing Phase 1 single-center trial in healthy volunteers that showed that a capsule with an improved release profile could deliver EDP1815 higher up in the small intestine. 

Benzinga · Mar 24, 2022